Albert Dashi

Dr Albert Dashi (Chief Scientific Officer) is Sequential’s co-founder. He completed his PhD in molecular genetics, epigenetics and stem cell research at the National University of Singapore (NUS) and the Genome Institute of Singapore in 2019. In 2014, he received the Singapore International Graduate Award from A*STAR for his PhD research and was also awarded the “Young Investigator” award. He also won the “Young Entrepreneur Scheme” award by P&G for his innovative and business driven ideas. Prior moving to Singapore for his doctorate program, Albert obtained his Masters in Biomedical Sciences at University of Bern, Switzerland. With an MSc Biomedical Sciences and >10 published papers on molecular genetics, epigenetics and stem cell research.

Pinidphon Prombutara

Pinidphon holds a Ph.D. in biochemistry from the University of North Texas. He was a research manager and lecturer at Omics Sciences and Bioinformatics Center, Faculty of Science, Chulalongkorn University, Bangkok, before joining Mod Gut Co., Ltd., a gut microbiome service-based company in Thailand. His current role is developing gut microbiome test and dietary recommendation applications based on an individual gut microbiome result, advancing One Health with new solutions for Thai people.

Patricia Conway

Dr Patricia Conway, BSc & MSc (Uni of Qld, Australia), PhD (UNSW Australia), is Visiting Prof at SCELSE at Nanyang Technological University, Singapore, Adjunct Prof at UNSW Australia and Chief Scientist/CEO and Founder of PC Biome Pte Ltd, Singapore. She is also Founder/Director and Research Director of two Biotech companies in Australia. She has successfully combined basic research and translational applications for over 30 years by being affiliated with university for supervision of doctoral students (>20 to date) and the basic research while being industry employed, or by working closely with industry while being university employed. She has over 100 publications in international peer reviewed journal. Several globally marketed products for gut microbiome modulation have been commercialised from her work, and are supported by the IP platform including over 20 primary patents.

Patricia’s research interests are gastrointestinal microbiology, probiotics and prebiotics, with particular emphasis on the importance of the gut microbiome for health and well-being. She has focused on mechanisms of bacterial adhesion, pathogen inhibition and immune modulation in animals and humans. In particular, health conditions linked to inflammation, infection and metabolic disorders and developing intervention strategies for improving health, especially in infants and the elderly.

Viduthalai Rasheedkhan Regina

Dr. Viduthalai Rasheedkhan Regina (@Vidu) is a Principal Research Fellow at the Singapore Centre for Life Sciences Engineering (SCELSE) at Nanyang Technological University (NTU, where he currently leads the skin microbiome research program. Dr. Vidu serves as the Dep. Research Director of L’Oréal-SCELSE joint research laboratory. He is also a SRIS researcher at the Skin Research Institute of Singapore.

Dr. Vidu carried out his Ph.D. in microbial adhesion and biofilm formation under the guidance of Prof. Rikke Meyer at the Interdisciplinary Nanoscience Centre (iNANO) at Aarhus University in Denmark. After a post-doc at Aarhus University, Denmark, and a brief entrepreneurial venture in Netherlands, he moved to Singapore and joined SCELSE-NTU in 2016.

Dr. Vidu’s research focuses on the development and study of niche-specific synthetic microbial communities, in vitro. By employing molecular techniques and community ecology frameworks, he investigates inter-species interactions facilitated by secreted metabolites to uncover novel targets and strategies for microbiome engineering.